HeartSciences(HSCSW)

Focus: HeartSciences is a public biotechnology company focused on electrocardiography-based diagnostics for metabolic diseases, specifically heart failure detection through its Myovista® WavECG™ platform. The company is early-stage with minimal revenue generation and operates from Southlake, TX.

Metabolic Diseases

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About HeartSciences

AI assessmentNot Hiring

No open roles listed right now. Follow HeartSciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$19K

FY2025

Pipeline & Clinical Trials

Myovista® WavECG™

Heart Failure

N/A

Clinical Trials (1)

NCT05068154Myovista vs NT Pro-BNP Heart Failure Referral Tool

N/A

Help build intelligence for HeartSciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage diagnostic innovation in an underserved cardiac space with proprietary ECG technology
Public company status provides potential equity upside and exit clarity
Focused pipeline with single lead program eliminates portfolio distraction

Watch Out For

Essentially pre-revenue ($19K FY2025) with minimal commercial traction and $6.6M annual cash burn
Zero active clinical trials and no defined development timeline for lead program indicate stalled progress
Extremely thin cash runway ($6M) with mounting losses suggests 12–18 month sustainability window

Generated by Claude from HeartSciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Cardiovascular

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$19K261%

R&D Spend

$3M(15476%)17%

Net Income

-$7M